-2,70 %
-2,58 %
-19,16 %
-17,40 %
-80,13 %
-79,84 %
-89,11 %
-89,80 %
-88,12 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Læs mereMarkedsværdi
90,35 mio. EUR
Aktieomsætning
262,48 t EUR
P/E (adj.) (26e)
-4,42
EV/EBIT (adj.) (26e)
-3,56
P/B (26e)
20,67
EV/S (26e)
20.109,28
Udbytteafkast, % (26e)
-
